WARF: P06036US

  • Assigned to WARF as biological material.

Tsp1 -/- Stz Mice, A Model For Diabetes


Nader Sheibani-Karkhaneh, Christine Sorenson

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in an improved animal model for the study of diabetic retinopathy.
OVERVIEWEffective and non-destructive treatments are needed for diabetic retinopathy, a major cause of blindness in the United States. Thrombospondin1 (TSP1), a matricellular protein that inhibits angiogenesis in vivo and is essential for proper retinal vascular development, is dramatically down-regulated in ocular samples from diabetic rats.
THE INVENTIONBased on this observation, UW-Madison researchers have developed a line of TSP1-negative mice that provides an improved animal model for the study of diabetic retinopathy. They induced diabetes in TSP1-/- mice by injecting them with a single dose of streptozotocin to destroy their pancreatic beta cells. The resulting TSP1 -/- mice develop diabetes-associated early vasculopathies of similar severity to those observed in a previous mouse model developed by the inventors, but after a shorter duration of diabetes.
  • Testing the effects of new compounds for treating diabetic retinopathy
  • Mice rapidly develop vasculopathies associated with diabetes.
  • Mice become useful models after three months of diabetes, avoiding issues associated with drug testing in aged mice.
  • Mice develop severe non-proliferative retinopathy, which may lead to a proliferative state (the final stage of diabetic retinopathy).
Contact Information
For current licensing status, please contact Jennifer Gottwald at or 608-960-9854.
The WARF Advantage

Since its founding in 1925 as the patenting and licensing organization for the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.